News from calliditas therapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

31 Jul, 2020, 11:27 BST Number of shares and votes in Calliditas Therapeutics

During July, Calliditas Therapeutics AB (publ) has issued 706,676 common shares as a result of the exercise of the over-allotment option within the...


24 Jul, 2020, 07:20 BST Calliditas reorganizes its management team

Calliditas Therapeutics AB (publ) ("Calliditas") today announced that it has reorganized its management team. From today, the company's management...


02 Jul, 2020, 08:05 BST Exercise of Over-allotment Option and End of the Stabilization Period

Citigroup Global Markets Inc. ("Citigroup"), in its capacity as Joint Global Coordinator, notifies that the stabilization period relating to...


30 Jun, 2020, 16:44 BST Number of Shares and Votes in Calliditas Therapeutics

During June, Calliditas Therapeutics AB (publ) has issued 9,230,770 common shares as a result of the initial public offering on The Nasdaq Global...


25 Jun, 2020, 17:53 BST Bulletin From the Annual General Meeting of Calliditas Therapeutics AB (publ)

The following resolutions were passed at Calliditas Therapeutics AB (publ) ("Calliditas") annual general meeting held today, on June 25, 2020, in...


25 Jun, 2020, 03:17 BST Citigroup Notifies That Stabilization Measures Have Been Undertaken in Calliditas Therapeutics' ADSs Traded on The Nasdaq Global Select Market

Citigroup Global Markets Inc. ("Citigroup"), in its capacity as Joint Global Coordinator, notifies that stabilization measures have been undertaken...


22 Jun, 2020, 07:14 BST CEO Renée Aguiar-Lucander Exercises Warrants and Invests SEK 15.7m (Appr. USD 1.7m) in Calliditas

Calliditas Therapeutics AB (publ) ("Calliditas") today announced that its CEO Renée Aguiar-Lucander will exercise warrants granted pursuant to...


13 Jun, 2020, 00:15 BST Citigroup Notifies That Stabilization Measures Have Been Undertaken in Calliditas Therapeutics' ADSs Traded on The Nasdaq Global Select Market

Citigroup Global Markets Inc. ("Citigroup"), in its capacity as Joint Global Coordinator, notifies that stabilization measures have been undertaken...


05 Jun, 2020, 08:08 BST Calliditas Therapeutics Prices its Initial Public Offering on The Nasdaq Global Select Market in the United States

Calliditas Therapeutics AB (publ) ("Calliditas") announced today the pricing of its initial public offering on The Nasdaq Global Select Market by way ...


01 Jun, 2020, 12:25 BST Calliditas Therapeutics Launches US IPO Roadshow and Targets a Capital Raise of MUSD 75

Calliditas Therapeutics AB (publ) will today launch an investor roadshow for a contemplated initial public offering of American Depositary Shares in...


14 May, 2020, 14:28 BST Calliditas Publicly Files Registration Statement With SEC for a Proposed Initial Public Offering in the United States

Calliditas Therapeutics AB (publ) ("Calliditas" or the "Company") has today publicly filed a registration statement on Form F-1 with the U.S....


14 May, 2020, 06:34 BST Calliditas Therapeutics: Interim Report Q1, 2020

"In the end of the first quarter of 2020 much of the activity at the company was focused on assessing and mitigating any potential impact Covid-19...


27 Apr, 2020, 07:16 BST Calliditas Provides a Corporate Business Update in the Context of the COVID-19 Pandemic

Calliditas Therapeutics AB (publ) ("Calliditas") today provided an update on its business activities and financial position as well as the...


06 Apr, 2020, 07:26 BST Calliditas Appoints New Chief Medical Officer

Calliditas Therapeutics AB (publ) ("Calliditas") today announced that Dr. Richard Philipson has been appointed as Chief Medical Officer (CMO) of...


01 Apr, 2020, 07:14 BST Calliditas Strengthens its US Commercial Organization

Calliditas Therapeutics AB (publ) ("Calliditas") today announced it has strengthened its operations in the United States with the addition of...


30 Mar, 2020, 13:19 BST Calliditas Moves its Annual General Meeting 2020 to June 25

Calliditas Therapeutics AB (publ) ("Calliditas") today announced that due to the recent Covid-19 pandemic, the Company has decided to move its Annual ...


03 Mar, 2020, 12:07 GMT Bulletin From the Extraordinary General Meeting of Calliditas Therapeutics AB (publ)

As part of the preparations for a potential offering of American Depository Shares in the United States and a concurrent listing on the Nasdaq Global ...


14 Feb, 2020, 06:18 GMT Calliditas Therapeutics - Year-End Report 2019

Recruitment for NefIgArd part A completed on plan and budget "In the last quarter of 2019, we achieved a major milestone: the full recruitment of 200 ...


22 Jan, 2020, 07:13 GMT Positive Opinion Received From EMA Paediatric Committee on the Paediatric Investigation Plan for Nefecon for the Treatment of IgAN

Calliditas Therapeutics AB (publ) ("Calliditas") today announced that the EMA Paediatric Committee (PDCO) has adopted a positive opinion on the...


09 Jan, 2020, 16:44 GMT Calliditas Submits Draft Registration Statement for the Listing of ADSs in the U.S.

Calliditas Therapeutics AB (publ) ("Calliditas" or the "Company") today announces that it has confidentially submitted a draft registration statement ...


23 Dec, 2019, 08:31 GMT The pivotal Phase 3 Clinical Trial NefIgArd Part A Fully Recruited

Calliditas Therapeutics AB (publ) ("Calliditas") today announced the full recruitment of all 200 patients required for Part A of the company's...


19 Dec, 2019, 07:22 GMT Completion of Recruitment of Part A of the Neflgard Pivotal Phase 3 Clinical Trial by Year End

Calliditas Therapeutics AB (publ) ("Calliditas") today announced that 198 out of a total of 200 patients required for Part A of the Company's pivotal ...


17 Dec, 2019, 11:07 GMT China IND Approval Triggers $5 Million Milestone Payment From Everest Medicines

Calliditas Therapeutics AB (publ) ("Calliditas") today announced that a $5 million milestone payment from its partner Everest Medicines II Limited...


14 Nov, 2019, 06:13 GMT Interim Report Q3, 2019

"This third quarter of 2019 saw us move steadily towards full recruitment of the NefIgArd study, despite a somewhat slower pace during the summer...


04 Nov, 2019, 07:21 GMT Calliditas Therapeutics Capital Markets Day Today November 4

Calliditas Therapeutics ("Calliditas") today hosts a Capital Markets Day in Stockholm, moderated by Lars Frick from Börsveckan. The Capital Markets...